Rena J. Eudy-Byrne, Ph.D.

Senior Scientist II

Rena joined Metrum in November 2015 after completing her Ph.D. in Biomedical Engineering at the University of Connecticut. Her dissertation work included extending a systems pharmacology model of bone and osteoporosis to be relevant for the development new therapies. Part of this work included linking simulated changes in bone mineral density to a hazard model of fracture in a Bayesian framework in order to predict the probability of fracture in osteoporosis patients. Analysis tools for establishing a priori identifiability of target-mediated drug disposition and other indirect response-type models were also part of this larger work. Rena brings 5 years of industry experience to the team, including work in preclinical development in metabolic systems and neuroscience and using systems pharmacology models to inform clinical decisions.

Recent publications by this scientist

Dose Selection of BI 765423 for Phase II Study in Idiopathic Pulmonary Fibrosis (IPF) Using PK–Target Engagement Modeling

October 19, 2026

Rena Eudy-Byrne¹, Elias Clark¹, Sabrina Wiebe², Giselle Benitez³, Julia Korell¹,³*, Nina Patel³, Fenglei Huang³
¹Metrum Research Group, Boston, MA, USA; ²Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

Presented at the 2026 American Conference on Pharmacometrics (ACoP 2026), an International Conference on Pharmacometrics in the US (ICoP – US), on October 12, 2026.

BI 765423 is a humanized monoclonal antibody targeted to block soluble IL-11 and is currently in development for the treatment of idiopathic pulmonary fibrosis (IPF). Our objective was to recommend a Phase II dosing regimen that results in 90% target engagement (TE) in at least 80% of patients at steady-state.

Download PDF

Population pharmacokinetics of nerandomilast in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

March 18, 2026

Population pharmacokinetics of nerandomilast in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

Megan Pane1, Curtis Johnston1∗, Rena Eudy-Byrne1, Tyler Dunlap1, Nikolas Onufrak2∗, Sonja Hartmann2∗, Steve Choy21Metrum Research Group, Boston, MA, U.S.A.,2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, U.S.A.

∗Affiliation during time of analysis

Mechanism of Action
• Nerandomilast (JASCAYD®) is an orally administered, preferential inhibitor of the
phosphodiesterase-4B (PDE4B) isoenzyme
• PDE4B hydrolyzes and inactivates cyclic adenosine monophosphate
Therapeutic Indication
• Approved by the U.S. FDA and China’s CDE for the treatment of idiopathic pul-
monary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
• IPF is a specific type of interstitial lung disease (ILD) and PPF is associated with a
subset of ILDs distinct from IPF
• Both IPF and PPF lead to lung scarring that progresses over time, with a median
survival time of 3-5 years
Chemical and Metabolic Properties
• Nerandomilast (R-enantiomer) contains a chiral sulfoxide group and undergoes a
minor level of metabolic chiral inversion following oral administration
• The resulting S-enantiomer is pharmacologically inactive
• Both nerandomilast and the S-enantiomer were characterized in this analysis

Integrated Two‑Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3‑DXd) Monotherapy in Patients with Solid Tumors

June 17, 2025

This work illustrates how integrated population PK modeling of antibody-conjugated payload and free payload analytes for an ADC can inform development strategies for targeted therapies—particularly in complex oncology settings.

Read Article